Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines

(2010) Hua Cheng et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage

(2009) Cheng-Yun Jin et al.   ANTI-CANCER DRUGS

Retracted: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines

(2009) Shirish M. Gadgeel et al.   CANCER

RETRACTED: Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents

(2009) Shadan Ali et al.   CANCER LETTERS

Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma

(2009) Sung-Jin Park et al.   CANCER LETTERS

Genistein and β-carotene enhance the growth-inhibitory effect of trichostatin A in A549 cells

(2009) Rong-Jen Shiau et al.   EUROPEAN JOURNAL OF NUTRITION

Evidence that low-dose, long-term genistein treatment inhibits oestradiol-stimulated growth in MCF-7 cells by down-regulation of the PI3-kinase/Akt signalling pathway

(2009) Nitharnie Anastasius et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals

(2008) Jian-quan Zhu et al.   CANCER LETTERS

Multi-targeted therapy of cancer by genistein

(2008) Sanjeev Banerjee et al.   CANCER LETTERS

Kaempferol Induces Cell Death Through ERK and Akt-Dependent Down-Regulation of XIAP and Survivin in Human Glioma Cells

(2008) Ji Cheon Jeong et al.   NEUROCHEMICAL RESEARCH

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA